Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2006-10-30
2009-02-10
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
C424S085100, C514S008100
Reexamination Certificate
active
07488473
ABSTRACT:
The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the polypeptides, conjugates, and nucleic acids.
REFERENCES:
patent: 4414150 (1983-11-01), Goeddel
patent: 4695623 (1987-09-01), Stabinsky
patent: 4885166 (1989-12-01), Meyer et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5539063 (1996-07-01), Hakimi et al.
patent: 5559213 (1996-09-01), Hakimi et al.
patent: 5747646 (1998-05-01), Hakimi et al.
patent: 5792834 (1998-08-01), Hakimi et al.
patent: 5834594 (1998-11-01), Hakimi et al.
patent: 5849860 (1998-12-01), Hakimi et al.
patent: 5985262 (1999-11-01), Kinstler et al.
patent: 6303344 (2001-10-01), Patten
patent: 6610830 (2003-08-01), Goeddel et al.
patent: 2004/0002474 (2004-01-01), Heinrichs et al.
patent: 2004/0030101 (2004-02-01), Bailon et al.
patent: 2004/0223950 (2004-11-01), Brugger et al.
patent: 0051873 (1982-05-01), None
patent: 0205404 (1986-12-01), None
patent: 0422697 (1991-04-01), None
patent: 0 510 356 (1992-10-01), None
patent: 0 593 868 (1994-04-01), None
patent: 0809996 (1997-12-01), None
patent: 0911033 (1999-04-01), None
patent: 20020067105 (2002-08-01), None
patent: 8302461 (1983-07-01), None
patent: 9206707 (1992-04-01), None
patent: 9524212 (1995-09-01), None
patent: 9903887 (1999-01-01), None
patent: 0042175 (2000-07-01), None
patent: 0052153 (2000-09-01), None
patent: 0069913 (2000-11-01), None
patent: 0125438 (2001-04-01), None
patent: 0187925 (2001-11-01), None
patent: 0244197 (2002-06-01), None
patent: 2004045648 (2004-06-01), None
Goeddel D.V., et al. The structure of eight distinct cloned human leukocyte interferon cDNAs. Nature, Mar. 5, 1981; vol. 290(5801):20-26.
Bailon P., et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjugugate Chemistry, Mar.-Apr. 2001; vol. 12 (2):195-202.
Allen G., Diaz M.O. (1996) Nomenclature of the human interferon proteins. J. Interferon Cytokine Res. Feb. 1996; 16(2):181-184.
Alton, K. et al. (1983) Production, characterization and biological effects of recombinant DNA derived IFN-alpha and IFN-gamma analogs. in The Biology of the Interferon System, 1983, eds. E. DeMaeyer and H. Schellekens, Elsevier Science Publications pp. 119-128.
Altrock B.W., et al. (1986) Antiviral and antitumor effects of a human interferon analog, IFN-alpha Con1, assessed in hamsters. J Interferon Res. Aug. 1986; 6(4):405-415.
Blatt L.M., et al. (1996) The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res. Jul. 1996; 16(7):489-499.
Chang C.C., et al. (1999) Evolution of a cytokine using DNA family shuffling. Nat Biotechnol. Aug 1999;17(8):793-797.
Cheetham B.F., et al. (1991) Structure-function studies of human interferons-alpha: enhanced activity on human and murine cells. Antiviral Res. Jan. 1991;15(1):27-39.
Diaz M.O., et al. (1996) Nomenclature of the human interferon genes. J Interferon Cytokine Res. Feb. 1996;16(2):179-180.
Fish E.N., et al. (1989) The role of three domains in the biological activity of human interferon-alpha. J Interferon Res. Feb. 1989;9(1):97-114.
Foser S, et al. (2003) Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS). Protein Expr Purif. Jul. 2003;30(1):78-87.
Gangemi J.D., et al. (1989) Significant differences in therapeutic responses to a human interferon-alpha B/D hybrid in Rauscher or Friend murine leukemia virus infections. J Interferon Res. Jun. 1989;9(3):275-283.
Henco K., et al. (1985) Structural relationship of human interferon alpha genes and pseudogenes. J Mol Biol. Sep. 20, 1985;185(2):227-260.
Meister A., et al. (1986) Biological activities and receptor binding of two human recombinant interferons and their hybrids. J Gen Virol. Aug. 1986; 67 (Pt 8):1633-1643.
Ozes O.N., et al. (1992) A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities. J Interferon Res. Feb. 1992;12(1):55-59.
Weck P.K., et al. (1981) Antiviral activites of hybrids of two major human leukocyte interferons. Nucleic Acids Res. Nov. 25, 1981; 9(22):6153-6166.
International Search Report dated Jul. 2, 2004 for related PCT application PCT/US03/36682 filed Nov. 17, 2003.
Written Opinion dated Sep. 15, 2004 for related PCT application PCT/US03/36682 filed Nov. 17, 2003.
Supplementary Partial European Search Report for related application EP 03811632, dated Mar. 3, 2006.
Brideau-Andersen, A. et al. (2007) Directed evolution of gene-shuffled IFN-α molecules with activity profiles tailored for treatment of chronic viral diseases. P.N.A.S. 104(20) 8269-8274, plus Supporting Information from the P.N.A.S. website.
Govindarajan Sridhar
Nissen Torben Lauesgaard
Patten Phillip A.
Viswanathan Sridhar
Kruse Norman J.
Maxygen Inc.
Maxygen, Inc.
Petithory Joanne R.
Saoud Christine J
LandOfFree
Interferon-alpha polypeptides and conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Interferon-alpha polypeptides and conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Interferon-alpha polypeptides and conjugates will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4061677